Anemia Management in Patients Receiving Chronic Hemodialysis

Seminars in Dialysis

Volumn 24, Issue 5, 2011, Pages 597-602

  Thakuria, Mayuri ^a   Ofsthun, Norma J ^a   Mullon, Claudy ^a   Diaz Buxo, Jose A ^a  

^a FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; IRON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ALGORITHM; ANEMIA; ARTICLE; HUMAN; RENAL REPLACEMENT THERAPY;

ALGORITHMS; ANEMIA; ERYTHROPOIETIN; HEMATINICS; HUMANS; IRON; RECOMBINANT PROTEINS; RENAL DIALYSIS;

EID: 80054679092     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2011.00975.x     Document Type: Article

References (18)

1. US Renal Data System, USRDS 2010: Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2010
2. Fishbane S, Frei GL, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26:41-46, 1995
3. ® (iron sucrose injection, USP) Prescribing Information. Fresenius Medical Care North America, October 2008
4. Juergensen P, Finkelstein F: The effectiveness of low-dose maintenance i.v. iron therapy: a dialysis facility's experience. Nephrol Nurs J 33:71-74, 2006
5. Park J, Chang JW, Lee JS, Chung HC, Yang WS, Lee SK, Park SK, Park JS: Efficacy of low-dose i.v. iron therapy in hemodialysis patients. Nephrology 14:716-721, 2009
6. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11:530-538, 2000
7. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR, the DRIVE study group: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin, and low transferring saturation: results of the Dialysis patients' Response to i.v. Iron with Elevated ferritin (DRIVE) study. J Am Soc Nephrol 18:975-998, 2007
8. Kapoian T, O'Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, Kopelman RC, Dahl NV, Coyne DW: Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19:372-379, 2008
9. DeVita MV, Frumkin D, Mittal S, Kamran A, Fishbane S, Michelis MF: Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Neprhol 60:335-340, 2003
10. Unger EF, Thompson AM, Blank MJ, Temple R: Erythropoiesis-stimulating agents - time for a reevaluation. N Engl J Med 362:189-192, 2010
11. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 255:2085-2098, 2006
12. Pfeffer MA, Burdmann EA, Chen CY, Copper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019-2032, 2009
13. Aronoff GR, Brier M, Mullon C, Keo P, Mooney A, Ofsthun NJ, Diaz-Buxo JA: Iron sucrose injection (Venofer) maintenance therapy in hemodialysis (HD) patients and erythropoiesis-stimulating agent (ESA) sparing. J Am Soc Nephrol 21:895A, 2010
14. Federal Register, Volume 76, No. 3, 2011
15. Gaweda AE, Nathanson BH, Jacobs AA, Aronoff GR, Germain MJ, Brier ME: Determining optimum hemoglobin sampling for anemia management from every treatment data. Clin J Am Soc Nephrol 5:1939-1945, 2010
16. Weinhandl E, Gilberton DT, Bradbury BD, Collins AJ: Hemoglobin variability and mortality: confounding by disease severity. Am J Kidney Dis 57:255-265, 2011
17. Ho WR, Germain MJ, Garb J, Picard S, Mackie M-K, Bartlett C, Will EJ: Use of 12×/month haemoglobin monitoring with a computer algorithm reduces haemoglobin variability. Nephrol Dial Transplant 25:2710-2714, 2010
18. Germain MJ, Nathanson BH, Garb JL: Assessing the benefits of frequent hemoglobin monitoring in CKD patients requiring hemodialysis. J Am Soc Nephrol 19:274A, 2008